<SEC-DOCUMENT>0001213900-15-008841.txt : 20151118
<SEC-HEADER>0001213900-15-008841.hdr.sgml : 20151118
<ACCEPTANCE-DATETIME>20151117174844
ACCESSION NUMBER:		0001213900-15-008841
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20151117
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20151118
DATE AS OF CHANGE:		20151117

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Actinium Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001388320
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				880378336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36374
		FILM NUMBER:		151239128

	BUSINESS ADDRESS:	
		STREET 1:		546 5TH AVENUE, 14TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036
		BUSINESS PHONE:		212-300-2131

	MAIL ADDRESS:	
		STREET 1:		546 5TH AVENUE, 14TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cactus Ventures, Inc.
		DATE OF NAME CHANGE:	20070130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k111715_actiniumpharma.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Pursuant to Section 13 or 15(d) of the</B><BR>
<B>Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Date of Report (Date of earliest event reported):
November 17, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>ACTINIUM
PHARMACEUTICALS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">(Exact name of registrant as specified in its
charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: Black 1.5pt solid; padding: 0; text-align: center; text-indent: 0"><B>Delaware</B></TD>
    <TD STYLE="width: 2%; padding: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: Black 1.5pt solid; padding: 0; text-align: center; text-indent: 0"><B>000-52446</B></TD>
    <TD STYLE="width: 2%; padding: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: Black 1.5pt solid; padding: 0; text-align: center; text-indent: 0"><B>74-2963609</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">(State or other jurisdiction<BR>
    of incorporation)</TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">(Commission File Number)</TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">(IRS Employer<BR>
    Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 49%; border-bottom: Black 1.5pt solid; padding: 0; text-align: center; text-indent: 0"><B>757 Third Avenue,
    21st Floor</B><BR>
    <B>New York, NY</B></TD>
    <TD STYLE="width: 2%; padding: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 49%; border-bottom: Black 1.5pt solid; padding: 0; text-align: center; text-indent: 0"><B>10017</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">(Address of principal executive offices)</TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: <B>(732) 243-9495</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1.5pt solid; padding: 0; text-align: center; text-indent: 0"><B>N/A</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">(Former name or former address, if changed since last report)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify; text-indent: -13.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;
</FONT>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify; text-indent: -13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify; text-indent: -13.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;
</FONT>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify; text-indent: -13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify; text-indent: -13.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;
</FONT>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify; text-indent: -13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify; text-indent: -13.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;
</FONT>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify; text-indent: -13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify; text-indent: -13.5pt"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify; text-indent: -13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify; text-indent: -13.5pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify; text-indent: -13.5pt"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 8.01 Other Events.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Actinium
Pharmaceuticals, Inc. issued a press release on November 17, 2015 announcing that it has submitted an Investigational New Drug
(IND) application with the U.S. Food and Drug Administration (FDA) for Iomab-B, a radioimmunotherapeutic that conditions Acute
Myeloid Leukemia (AML) patients for a Hematopoietic Stem Cell Transplant (HSCT), commonly referred to as a Bone Marrow Transplant
(BMT). A copy of the Company&rsquo;s press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated
into this Item&nbsp;8.01 by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #4A442A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 9.01 Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>(d) Exhibits. </I>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0; width: 9%">Exhibit&nbsp;99.1</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 1%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 90%">Press release of Actinium Pharmaceuticals, Inc., dated November 17, 2015</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center">SIGNATURES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dated: November 17, 2015</FONT></TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>ACTINIUM PHARMACEUTICALS,
    INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>/s/
    Kaushik J. Dave</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name: Kaushik J. Dave</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:&nbsp;&nbsp;Chief Executive
    Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>f8k111715ex99i_actinium.htm
<DESCRIPTION>PRESS RELEASE OF ACTINIUM PHARMACEUTICALS, INC.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</P>

<P STYLE="margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; text-align: center"><IMG SRC="ex99i_01.jpg" ALT="">&nbsp;</P>

<P STYLE="margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 12pt Times New Roman, Times, Serif"><B>Actinium
Submits Iomab-B IND Application to the U.S. FDA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Company
Gearing Up For Pivotal, Phase 3 Clinical Trial </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NEW
YORK, NY &ndash; November 17, 2015</B> Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) (&quot;Actinium&quot; or &quot;the Company&quot;),
is a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers.
Actinium announced today that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration
(FDA) for Iomab-B, a radioimmunotherapeutic that conditions Acute Myeloid Leukemia (AML) patients for a Hematopoietic Stem Cell
Transplant (HSCT), commonly referred to as a Bone Marrow Transplant (BMT). Pending the FDA&rsquo;s acceptance of the IND filing,
Actinium will initiate a single, pivotal Phase 3 clinical study in refractory and relapsed AML patients over the age 55. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #3B3838">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ldquo;We
are excited to have submitted the Iomab-B IND application to the FDA,&rdquo; said Kaushik J. Dave, Ph.D., MBA, CEO of
Actinium. &ldquo;We focused heavily on Iomab-B in 2015 and overcame our previous manufacturing hurdles, which gave us great
confidence when we met with the FDA for our pre-IND meeting. Our filing, well ahead of our year end guidance, is a great
milestone for Actinium.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Sandesh
Seth, Actinium&rsquo;s Executive Chairman commented, &ldquo;This much anticipated regulatory filing is an important one that marks
the first step in Actinium&rsquo;s transition to a later development stage biopharmaceutical company. As we prepare for the pivotal
Phase 3 clinical trial for Iomab-B in 2016, we have added key members to our executive, regulatory and clinical operations teams
and will continue to add selectively. This strengthening of the company will enable us to meet our goals of efficient execution
of not only the Iomab-B program but also of the Actimab-A Phase 2 trial planned for early 2016, as well as other pre-clinical
and clinical programs expected for next year.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #3B3838"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #282726"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white"><B>About
the Iomab-B Pivotal, Clinical Trial</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #282726"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">Iomab-B
will be used in preparing patients for hematopoietic stem cell transplantation (HSCT), the fastest growing hospital procedure
in the U.S. The Company established an agreement with the FDA that the path to a Biologics License Application (BLA) submission
could include a single, pivotal Phase 3 clinical study, if it is successful. The population in this two arm, randomized, controlled,
multicenter trial will be refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55. The trial size was
set at 150 patients with 75 patients per arm. The primary endpoint in the pivotal Phase 3 trial is durable complete remission,
defined as a complete remission lasting at least 6 months and the secondary endpoint will be overall survival at one year. There
are currently no effective treatments approved by the FDA for AML in this patient population and there is no defined standard
of care. Iomab-B has completed several physician sponsored clinical trials examining its potential as a conditioning regimen prior
to HSCT in various blood cancers, including the Phase 1/2 study in relapsed and/or refractory AML patients. The results of these
studies in over 300 patients have demonstrated the potential of Iomab-B to create a new treatment paradigm for bone marrow transplants
by: expanding the pool to ineligible patients who do not have any viable treatment options currently; enabling a shorter and safer
preparatory interval for HSCT; reducing post-transplant complications; and showing a clear survival benefit including curative
potential.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #282726"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #282726"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #282726"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white"><B>About
Iomab-B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">Iomab-B
is a radioimmunoconjugate consisting of BC8, a novel murine monoclonal antibody, and iodine-131 radioisotope. BC8 has been developed
by the Fred Hutchinson Cancer Research Center to target CD45, a pan-leukocytic antigen widely expressed on white blood cells.
This antigen makes BC8 potentially useful in targeting white blood cells in preparation for hematopoietic stem cell transplantation
in a number of blood cancer indications, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic
leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin's disease (HD), Non-Hodgkin lymphomas (NHL) and multiple myeloma (MM).
When labeled with radioactive isotopes, BC8 carries radioactivity directly to the site of cancerous growth and bone marrow while
avoiding effects of radiation on most healthy tissues.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>About
Actinium Pharmaceuticals </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Actinium
Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload
immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary
delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals
in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be
used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant.
The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients
over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is
continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter
trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Forward-Looking
Statements for Actinium Pharmaceuticals, Inc. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This
news release contains &quot;forward-looking statements&quot; as defined in the Private Securities Litigation Reform Act of 1995.
These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results
to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product
development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may
differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events, or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Steve O'Loughlin</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Senior Director,
Finance and Corporate Development</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Actinium
Pharmaceuticals, Inc.</FONT><BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>soloughlin@actiniumpharma.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99i_01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99i_01.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !Y 24# 2(  A$! Q$!_\0
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M(FBBE$<JB2-'RHZ*OSN'Q/T_5'T 4445J 4444 %%%% !1110 4444 %%%%
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ML<<:JD<:*$1$0!51%4!555 "J      !3J**F&[]/U0!1116H!1110 4444
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MK3_A([/5;&SN_B+XHLQ]I\,S6D'A/2+J#7FUZ32/PJ%[^1]R?Q;^$?C#\5_
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MWU+1M3@L]<T*^T_5[&WNET_XB3Q[TXKS;YU,,U_ZKP?#>0O_ )E6#^4*B_\
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MK:[XAU[5[J74-9U[7=6O9);O4=3U*\FFN[Z\N)'DFED8DA0JK_?=_P &W_\
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MU=\-/B!X_P#[6^ WC+2OBO\ !_0_&][=^$/@I;Z?8^ OA1<>#-4U#5)?"(\
MZ9H]U;VR6JZO>:W>17M[J'S=_P %9/VT_C=\./V>_P#@HQ\4/A9^UY\3?B7^
MTM^S/^UI\%[#0_&'[.&K>)?A9^S/^Q/\/]4^+7@_PEX5_9H\36>I>+;+1_VC
M/CCXN\/SZ[J7QU6'PO\ $!+/5?$:Z1KT/@CP_P"#M)T:[ /[2J*_GT\1?M3>
M+/VB_P#@MGH?_!/3XB_$/Q7\+_@'X%_8*MOVCO#O@KP)XRUOX9ZO^U%\9/%O
MBG3-%U"YN_'W@[5M%\9:EX%^%OA(^*'TWP)X5US2([WQ;H'B3Q%XEDUFP\,6
MECIWR?\ M;?$G]HS]BSQY_P2Y_X)W>'?VW_&WQR\"_M,_MD_'OPM\7_VA_B_
M\0+SP_\ $*QT'P-IOA'Q5\)OV/?&_P 9OA[=7_C[1+K7]2\=Z+H>N^([;4=&
M^)WBFPCT_3;;4/#7AW5[G3T /ZNZ*_F(_;R^'W[=7[%__!,O_@J'\1_%7[8O
MB>XC\+P>%?C;^R#9?"SXD_%B/XI_LUM<ZK:^'O$_@/5_C%XLUE_&WQ/^%NHZ
ME>-?>$_#WC1=030[:+5=(%Y=PV.B-HTWQT_: ^,/A3]L#_@W'M/#W[07Q8LK
MC]K/PKXAA_:)\"0_$S7IO"'Q9T7PO^S;X+\5:7KWBGP&^H2>'Y-0E\7^)-5O
MKSQ!:Z9:76M7DD:WUS>'2[$60!_2POB'0Y=7U/PY:ZOI=YXET;2M.UO4_#5K
MJ5C+K]AI.LS:K:Z)J-[I7V@7EE8:U=Z'K-II-]=Q06=_<Z3J<-M/(^GW8A^>
M?V0/V@O&G[3GP3TKXL>/_P!F[XR?LH^)=0\1>+M"N?@]\=]/TS3?B!IMMX9\
M07NC66NW-MI5W=V_]E>)+:UCU72)]R+<6LPFM&O=->QU2_\ Y_?^":'P/U#Q
MQ_P5E_X+UZG>?';]IS3=>^'WQ7^ /@7PIK=C\:?$&H7%OHGB[X._$:\L8=2T
M#Q/#K_A/Q.G@&?5KV7X46/BCPUK6B^ H[CRM"TQ$W;_A;X4?\%//VN/!'_!%
MW]@SQK\0/C_\13XO_;,_X*=:_P#LM_'#]LCQ9J=IJ?C3X-_ K5?CS\0].\6Z
M_H>N:OIUSX?\*>)D\)^%;CP]X,U632TT'P+I$&IWFA6.GWFD:+]B /[BJS]7
MOI=+TK4]3@TS4-:GT[3[V^AT?2%LVU75I;2VEN(],TQ=1O-.T]M0OWC%K9+?
M:A8V9N98A<WEK!OG3\@_C-\%_%/[(;?M8?'CX5?\%%]9^$N@>)/V2[^^\,?#
M#]K#QIKWQP^#OP(\4> M2T.W\6?M<Z.OCCQ5X@^(NI0Z5H>I:?::QX-L6E\'
MZ]XXUW39-=-_)K^DZ1:_F1^RQ^U9\1D_X*_?L _#;X??%K]IGQ+^S;^TY_P3
MA\:^//$^H?M&^+]99/VDO$?A;5M7NO"/[56A_!KQ-XK\17_P7F^)<^FP7'AF
MS72O 3ZGX0U"VTVQ\&Z=I4=J)P#]RO\ @GQ^W]X+_P""AO@'XU_$'P1\,/B3
M\)K/X)_M)?$G]F?7?#?Q6'A>#Q?-XO\ A98>%YO$][=:?X1U_P 4:1ID$6J>
M(Y='CLUU[49C+I4]RTHBN(5'WS7\4W[%FK_M/V'_  3V_P""G^D_LE>*O#.A
M_'/6_P#@O7^T1H_A3P1XA^)=E\%==^.NCV/CSX=>*_B)^SU\-?BK?3V9\#_$
MWXJ^!?#OB+0/#^N6%U:Z[9P-J4>@WVEZS-8:G9_II_P3"_X*"_#6WO\ _@H&
M?VF[S]I3]B75/V?-<^"WC'XN?L[_ +>WQ+'BCP9^S#HWQ"\/ZCH.B:O\(_V@
M_&FL/>>)/A3\6M9T1-5TO1]?GM5TOQ3/,WA#[?X?\4Z/#; ']$M?B7^SY_P5
MQ^)'QT_X*-_%S_@FY<_L2^(/!/Q'_9\T32?&7QN^(%Q^T!\.O$'@KPGX$\1Z
M=X7U/PSX@T&VT_1+;7/&-]K5OXU\-*- L;*RN],FNKV+6)[%[ B?]G/#WB'0
M/%V@Z+XJ\*:YI'B;PQXDTJPUWP]XC\/ZE9ZSH6O:)JMK%?:7K&C:OITUS8:G
MI>HV4\-W87]E<3VEW;313V\LD4BN?Y6OV#&^V?\ !TQ_P6=C0W%L5_9@^!%H
M9E54FB?_ (1+]G11- 765,X(E@:1&5@%<QLO! /ZO:*_BS^'T7[5_P 9?V6/
M^"^_Q!^(7_!0C]N.[\:_\$_/VFOVP/#W[-FI^%?BY#\-XM!?]GGX8V?B[P?>
M>)[3X;>'/"<'BFQNSI.G6'B'P3<0V?@ PR:QK-CX6LO$6O7NL+]*>!O^"AOQ
MP_:&^+?_  0+_9A^,OQ7\0?"SP3^VW^Q+;?M._'WQ]X-U,_#7Q%^T=\8-)^%
MMK>>'O@EI?CC13I>H^!]%UGQ)!<^,O&>D> K_1-?\7C6/#?@W3M1TS3-2DL-
M7 /ZN**_/3]G_P &^"_V'K7]I%/BU^WCJ_Q%^&^H_&*S\:^&M'_:8^*GAV:X
M_97\._$B"VB\*_!L?$;QMXFNO%6H^&]5U;SI/A^/'NK1ZA/I\EEI6DQ7]S%?
M:GJOZ$HZ2(DD;K)'(JO'(C!T=' 971E)5E92"K D$$$$@T .HHHH *^7OA;^
MQC^S9\%?B3\1_B_\,?AW/X7^)7Q? /Q1\71>./B)J>I>/9H[>*RL[WQ2NM^+
M=2M-7U/2=/@ATO0=5N[:34O#^D11Z3HEUI^FHMJ/J&B@#X-^%_\ P3%_83^#
M/Q>\0_'SX:_L]>'O#7QC\8V^N6?C?X@KXF\?ZMK_ (]LO$L$EOKUAX_EUWQ9
MJ<'CNPU6.4M=V/BZWUFTDF2&Y$(N;>WECPO@O_P2>_X)X?L\?$:V^*?P8_9?
M\%^!?%&F^);KQGH%AI^M>.+[P!X0\8WD,UM-XN\"?"76?%6I?"KP%XH6WGFM
M[;Q#X,\&:%J]G!*\5G>01L5K]#Z* /A&]_X)F?L-7WQ%^.GQ7;X!:-9>//VE
M[*_L?CEK&C>+/B)H%K\0$UB.QAU^[U'P_H?B_3O#>G:OXHM].MK3Q=KNA:1I
M6M>+;+[38^)+_5+2^O8;CE=3_P""2G_!/#6/A;\/_@CJG[-/AZ]^$'PH\377
MC+X9_#:?QC\36\&^ _%=V[2/XA\*:"/&PL-#U:WFENKC3KRPA@FTJYU#5;G3
M&M+C5M3DN_T8HH ^-==_X)]_LB>)/C;<?M(ZQ\)/M/QYN? \OPT?XL1>/?B=
M8^-HOA]-I\NFR^#+/6=/\:6MQ8>&WAGGNCI-B;>S_MB>;7_*_MR6346Y[PE_
MP3-_82\#? WXK_LS^&OV;_!=G\ OCA,]W\4_A-=WWBK6O!GBS4I;B.\EUR?2
M=<\0:C'IGB.2_M[/4Y/$FB-IFO/JNG:5JK:B=1TK3KFU^ZZ* /SS\"?\$H?^
M">'PX\0_"'QAX8_9:\!-XQ^ MMJ5K\(_&7BB^\7>/?&'@J/5);&2:2P\5^._
M$GB3Q!>7=FNG6=KH=_JVHZA?>&]/C?3/#UQIFG3W%K+U/A;_ ()M_L4^"O"_
MQW\&>%?@A9:)X:_:>N[J_P#V@]-LO&WQ+4?%[4-0N+BXU?4?&]W)XSDO]8U'
M7_MEW:^)+^:Z%YXETRZN=(UZ;4=+GELW^XZ* /@O5_\ @F)^PGK_ ,'_ (6?
M #6/V?-"U#X,_!#Q>/'WPA^'D_BKXA?\(_\ #GQC$ACL?$'A*%/%ZSZ/?Z,K
MSGPZ]K.D?AI[W49- CTV34]0:Y^L_B!\+/ WQ2^''B#X2>/-'GU_X?\ BG0?
M^$9\0:&^MZ_ITVIZ&4BC>QGUS2=4L/$*^?'"B7-S#JT5W=(9%N+B59IA)Z#1
M0!\2_LM?\$X_V)OV)M;USQ#^RG^S]X5^"&H^)=-FTG7H_!FJ>+8=)U2UN+C3
M+F:2Z\/ZAXAO] ;49)-'TQ#K"Z8NK?9[.*T%\+3="W:_$?\ 8J_9B^+GQS^&
M_P"TO\1?A99>)OCK\']X^%OQ(N?$GC2SUSP EQ&T&H1>%8],\1V6FZ/!K=J[
MV7B."SL(X?$M@[V&OQZE9NT!^I:* /A*[_X)F?L+7[?M(-J/[//AG4S^U]I/
M]B?M,?VIKWCC4A\9K&.]&HZ>_C-;[Q1<+>:GH-YF7PMK=N+76O"2O)#X9U#2
M8))(VX[P5_P2+_X)Q_#S5/@?K_A']EGP7I?B3]F^XU>Y^"_BN;7O'VK>+_!;
MZSIUEI;Q+XMUKQ;J/B37[/1[/3=.'@^P\4ZIK=CX$NM/L;_P5;Z!?VEO<Q_H
M]10!\C? +]A']E']ENV^(UE^S[\)X/A9:?%RZUC4_B1;>&O&'Q!6'Q;KWB".
M&'6_%>I1WWBR\4>-=4BMK>.\\;6HM_%LRV\ ;6<0Q[>"T/\ X)@?L'^&O@I\
M1/V<="_9ZT#2_@9\6_$Z^,_B9\,+7Q3\0E\*>-_$Y1DNM7\0V#>+V-_/JN8Y
M->CDE^S>(;BUT^YUR'4+C3;"6V^]J* /B77/^"<W[&/B71_@!H.O?!.RU72_
MV5[N/4/V=H+SQI\2))?A!?P75M=6=[X+O?\ A,1?:9=Z:;.SL](N?M,LVCZ3
M:6VB:6]IH\$5BGENN_\ !'?_ ()G^)_%GQ\\:^(?V1?ASK&N_M/RZ]>_')=0
MOO&5QH'C;6_$\\]WK?BU?"+^)SX2\+^.KV]N[V_7Q]X-T3P]XTM-0OK_ %"R
MUZVO+Z[GF_2RB@#\_/BE_P $KO\ @G[\9O!7P0\ _$']FCP?J.B_LV>'['PK
M\"-5T/6O&_@CQ]\+O#FGQ6\4.C^%?BGX&\4^&_B=9V,YM8KC489/%TPU>^,^
MH:J;V_NKFYFZ#QY_P35_81^)W[.VF_LH>._V8_AIXC^ >C:])XNTGP-=V6I0
MSZ;XUN)KN>]\>V7C&RU*U\=VWQ!U.;4-0EUCQ[%XG7QAK+ZA?G5-;O/MMUYO
MW'10!\>^ _V OV/?AO\ !KXD? #PW\#?#5S\*?C%H\WA_P"+'A[QEJ7BCXDZ
ME\2=%ETN318M,\;^,OB+KWBKQOXFL]/TR66TT:+6/$=VNA++*^B_8)9'D;QS
MP5_P2!_X)L?#^3X1S^'_ -DSX?7-Y\!]0U/4OA%J7B[4O&OQ"U?P-<:I#I%L
M\6E:QX_\4>)M4ET[3;?0M+@\-:1J%W>:5X2A@EC\+66CI>7HN/TEHH ^*-;_
M ."=/[&&O_'OXB?M07GP0TNT^/7Q9\-V?A7XC?$?P_XK^('A35?%FF:?X>?P
MC87>I6/A?Q9H^ACQ+9>%99_#5IXTM=+M_&%OH-S=Z1%KJ6%W<P2Y?AO_ ()E
M_L&>$_V=_%W[)>C?LR?#O_AFKQS?#5?$7P4U9-;\1> )-66Z.H+K&D:'XBUC
M58?#&L+J9_M9=6\,'1]176%35UN1J2)=+]UT4 ?GYX _X)7_ + /PT^%_P 2
M_@WX7_9O\,S_  _^,'@1?A=\1--\8^)?B#\2-8U_X:12-<6OP^B\9?$7Q=XJ
M\:Z'X+TZ\8:AI'ACP]XATG1='U2&VU32K*SU&UMKF+E?"?\ P1W_ .":O@>3
MX*W7AC]E/P;INK_L[:EJ.J_!CQ,_B3XBZAXR\"W.HZ?9:8(+'QKJ?C*]\6ZC
MI6CVNFZ<WA30]<UK5-%\%WMA9:GX1T_1-2M8+M/TMHH _/;0?^"4_P#P3]\+
M^ _'WPR\/?LW>'-'\#_$[QYX?^*OC71+'Q5\18?[4^*WA;6;3Q!H'Q5M-3'C
M'^V-!^*&FZS865]%\1?#NH:5XSDEM+9;C6Y8H8XUYO\ :<_X)\_"OQ=^RO\
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/:*J@  5<HH **** /__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
